 |
274 Diseases |  |
1060 Trials |
|
1060 Trials |  |
12189 News |  |
| «12345678910111213...178179» |
- albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Valproic acid combinEd with Simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic Pancreatic Adenocarcinoma patients-VESPA trial (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_3211;
- Vyloy (zolbetuximab) / Astellas
Zolbetuximab With Gemcitabine + Nab-Paclitaxel (GN) in First-Line Treatment of Claudin 18.2 (Hall 6 - Poster area) - Jul 18, 2024 - Abstract #ESMO2024ESMO_3209;
- | INBRX-106 / Inhibrx Biosci
Phase classification, Combination therapy, Metastases: KEYNOTE A99: Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda (clinicaltrials.gov) - Jul 18, 2024
P1/2, N=333, Recruiting, Sponsor: Inhibrx Biosciences, Inc
Phase classification: P1 --> P1/2
- | adebrelimab (SHR-1316) / Jiangsu Hengrui Pharma
New P2 trial, Metastases: RICE: Adebrelimab (clinicaltrials.gov) - Jul 18, 2024
P2, N=48, Recruiting, Sponsor: Fujian Medical University Union Hospital
- | Aqupla (nedaplatin) / Simcere, adebrelimab (SHR-1316) / Jiangsu Hengrui Pharma
New P2 trial, Metastases: Adebrelimab Combined With Albumin Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable ESCC (clinicaltrials.gov) - Jul 17, 2024
P2, N=65, Not yet recruiting, Sponsor: Harbin Medical University
- || Tyvyt (sintilimab) / Eli Lilly, Tozaride (Rhenium (Re) 188 P2045) / Andarix
P2 data, Journal, IO biomarker: Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104). (Pubmed Central) - Jul 17, 2024
Informed circulating tumor DNA (ctDNA) detection in EGFR-mutant NSCLC could help identify patients nonresponsive to neoadjuvant immunochemotherapy. These findings provide supportive data for the utilization of neoadjuvant immunochemotherapy and insight into immune resistance in EGFR-mutant NSCLC.
- | albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Trial completion date, Trial primary completion date, Surgery, Metastases: A Study of Gemcitabine/Nab-paclitaxel and Radiation Therapy Followed by Surgery in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov) - Jul 17, 2024
P1/2, N=30, Active, not recruiting, Sponsor: University Health Network, Toronto
These findings provide supportive data for the utilization of neoadjuvant immunochemotherapy and insight into immune resistance in EGFR-mutant NSCLC. Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024
- ||| Clinical guideline, Journal: Consenso de expertos basado en la evidencia: perfilamiento y manejo del carcinoma epitelial de ovario de alto grado avanzado. (Pubmed Central) - Jul 16, 2024
Trial completion date: Jun 2024 --> Dec 2024 | Trial primary completion date: Jun 2024 --> Dec 2024 Se sugiere utilizar bevacizumab u olaparib m
- | Tyvyt (sintilimab) / Eli Lilly, Aqupla (nedaplatin) / Simcere
New trial: A single-arm, Phase II exploratory clinical study of Sintilimab in combination with albumin-paclitaxel and nedaplatin for neoadjuvant treatment of esophageal cancer (EUDRACT) - Jul 16, 2024
P=N/A, N=132, Recruiting, Sponsor: Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences; Shandong Cancer Hospital and Insti
- | Tyvyt (sintilimab) / Eli Lilly
New P2 trial: An open, single-arm clinical study to explore the safety and efficacy of sintilimab in combination with albumin-paclitaxel/cisplatin for neoadjuvant treatment of esophageal cancer (EUDRACT) - Jul 16, 2024
P2, N=46, Recruiting, Sponsor: Friendship Hospital Affiliated to Capital Medical University; Friendship Hospital Affiliated to Capital Medical University
- | AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: A phase II study for Albumin Bound Paclitaxel plus Camrelizumab (SHR1210) as therapy in patients with unresectable locally advanced or metastatic urothelial carcinoma (EUDRACT) - Jul 16, 2024
P2, N=60, Recruiting, Sponsor: Sun Yat-Sen University Cancer Center; Sun Yat-Sen University Cancer Center
Se sugiere utilizar bevacizumab u olaparib m Not yet recruiting --> Recruiting
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open: A prospective clinical study evaluating pembrolizumab combined with chemotherapy (cisplatin or carboplatin + nab-paclitaxel) in first-line treatment of patients with recurrent and metastatic squamous cell carcinoma of the nasal cavity and paranasal sinuses (EUDRACT) - Jul 16, 2024
P2, N=20, Recruiting, Sponsor: Cancer Hospital Chinese Academy of Medical Science; Cancer Hospital Chinese Academy of Medical Science
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Tevimbra (tislelizumab-jsgr) / BeiGene
Enrollment open, Enrollment change: A prospective clinical study evaluating the efficacy and safety of tislelizumab combined with nab-paclitaxel and cisplatin induction chemotherapy in the treatment of newly treated locally advanced hypopharyngeal carcinoma (EUDRACT) - Jul 16, 2024
P2, N=40, Recruiting, Sponsor: Cancer Hospital Chinese Academy of Medical Science; Cancer Hospital Chinese Academy of Medical Science
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | N=20 --> 40
- | capecitabine / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Trial completion, Phase classification: Nab-paclitaxel plus capecitabine as first-line treatment of recurrent/metastatic cholangi ocarcinoma: a multi-center, open label, single-arm study (EUDRACT) - Jul 16, 2024
P2, N=46, Completed, Sponsor: Beijing Cancer Hospital; Beijing Cancer Hospital and Institute
Not yet recruiting --> Recruiting | N=20 --> 40 Recruiting --> Completed | Phase classification: P4 --> P2
- | AiRuiKa (camrelizumab) / HLB Bio Group
Trial completion, Phase classification: A Trial Of Neoadjuvant Chemotherapy With Or Without Camrelizumab In Patients With Resectable Esophageal Squamous Cell Carcinoma (EUDRACT) - Jul 16, 2024
P3, N=390, Completed, Sponsor: Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences
Recruiting --> Completed | Phase classification: P4 --> P2 Not yet recruiting --> Completed | Phase classification: P4 --> P3
- Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
Effects of trastuzumab deruxtecan (T-DXd) vs choice of chemotherapy (TPC) on patient-reported outcomes (PROs) in hormone receptor-positive, HER2-low or HER2-ultralow metastatic breast cancer (mBC): Results from DESTINY-Breast06 (Barcelona Auditorium - Hall 2) - Jul 16, 2024 - Abstract #ESMO2024ESMO_1559;
P3
Conclusions T-DXd preserved QOL while delaying deterioration in physical/role functioning and pain vs TPC, albeit with more gastrointestinal symptoms. QOL data complement the efficacy/safety of T-DXd after ?1 ET in patients with hormone receptor
- | carboplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
New trial: The efficacy and safety exploration study of sequential administration of albumin-bound paclitaxel and carboplatin with PD-1 monoclonal antibody injection based on immune induction strategy in first-line treatment of advanced squamous non-small cell lung cancer (EUDRACT) - Jul 15, 2024
P=N/A, N=30, Not yet recruiting, Sponsor: the First Affiliated Hospital, Zhejiang University School of Medicine; the First Affiliated Hospital, Zhejiang University School of Medicine
- | Tevimbra (tislelizumab-jsgr) / BeiGene
New trial: Tislelizumab Combined With Chemotherapy Versus Standard Three-Drug Chemotherapy As Neoadjuvant Therapy for Resectable Stage II-III Esophageal Squamous Cell Carcinoma: A Phase II Open-Label, Randomized Controlled Clinical Study (EUDRACT) - Jul 15, 2024
P=N/A, N=74, Not yet recruiting, Sponsor: Fujian Provincial Hospital; Fujian Provincial Hospital
- | Focus V (anlotinib) / Advenchen, Sino Biopharm
New trial, Metastases: A prospective, single arm, multicenter, phase II clinical study of the combination of anlotinib and albumin bound paclitaxel for second-line treatment of advanced gastric cancer (EUDRACT) - Jul 15, 2024
P=N/A, N=40, Not yet recruiting, Sponsor: Chizhou people's Hospital, Anhui Province; Chizhou people's Hospital, Anhui Province
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
New trial: A prospective, single-arm, exploratory clinical study of toripalimab combined with chemotherapy in neoadjuvant therapy for head and neck squamous cell carcinoma (EUDRACT) - Jul 15, 2024
P=N/A, N=51, Recruiting, Sponsor: Shandong Second Provincial General Hospital; Shandong Second Provincial General Hospital
- | Enweida (envafolimab) / 3DMed, Tracon Pharma, Ascletis, Epidaza (chidamide) / Chipscreen
New trial: Envafolimab combined with Irinotecan or albumin-paclitaxel and Chidamide as second-line therapy in advanced and metastatic gastric cancer: A single-arm, exploratory, phase 2 trial (EUDRACT) - Jul 15, 2024
P=N/A, N=30, Recruiting, Sponsor: First affiliated hospital of Soochow university; First affiliated hospital of Soochow university
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P4 trial: An exploratory study of camrelizumab combined with albumin-bound paclitaxel in the second-line treatment of advanced esophageal squamous cell carcinoma (EUDRACT) - Jul 15, 2024
P4, N=40, Completed, Sponsor: Cancer Hospital Affiliated to Shandong First Medical University; Cancer Hospital Affiliated to Shandong First Medical University
- | albumin-bound paclitaxel / Generic mfg.
New P4 trial: Clinical study of pyrrolitinib maleate tablets combined with albumin paclitaxel in adjuvant treatment of HER2 positive early breast cancer (EUDRACT) - Jul 15, 2024
P4, N=150, Not yet recruiting, Sponsor: Weihai Municipal Hospital; Weihai Municipal Hospital
- | AiRuiKa (camrelizumab) / HLB Bio Group
New P3 trial: A single-center, open-label, randomized controlled phase 3 clinical study of neoadjuvant chemotherapy combined with immunotherapy for cervical lymph node dissection in upper thoracic esophageal squamous cell carcinoma (EUDRACT) - Jul 15, 2024
P3, N=420, Recruiting, Sponsor: The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University
- | AiTan (rivoceranib) / HLB Bio Group, adebrelimab (SHR-1316) / Jiangsu Hengrui Pharma
New P2 trial: The efficacy and safety study of adebrelimab in combination with chemotherapy and apatinib for perioperative treatment of lung sarcomatoid carcinoma (EUDRACT) - Jul 15, 2024
P2, N=25, Recruiting, Sponsor: Tianjin Medical University General Hospital; Tianjin Medical University General Hospital
- | Tevimbra (tislelizumab-jsgr) / BeiGene
New P2 trial: A prospective, single-arm, phase II study to evaluate the efficacy and safety of Tislelizumab plus chemotherapy induction, followed by surgery or radiotherapy, and Tislelizumab (EUDRACT) - Jul 15, 2024
P2, N=55, Not yet recruiting, Sponsor: West China Hospital of Sichuan University; West China Hospital of Sichuan University
- | adebrelimab (SHR-1316) / Jiangsu Hengrui Pharma, Itari (linperlisib) / Shanghai YingLi Pharma
New P2 trial, IO biomarker, Metastases: Adebrelimab Combined with Linperlisib and Nab-paclitaxel for second-line treatment of NSCLC: Single-arm, Exploratory Clinical Study of Adebrelimab Combined with Linperlisib and Nab-paclitaxel in Advanced NSCLC Progressed on Prior Immunotherapy (EUDRACT) - Jul 15, 2024
P2, N=33, Recruiting, Sponsor: Cancer Hospital Affiliated of Shandong First Medical University; Cancer Hospital Affiliated of Shandong First Medical University
- | recaticimab (SHR-1209) / Jiangsu Hengrui Pharma, adebrelimab (SHR-1316) / Jiangsu Hengrui Pharma
New P2 trial: A Phase II Clinical Study on the Perioperative Treatment of Resectable NSCLC with Adebrelimab Combined with Carboplatin, Albumin Paclitaxel, and Recaticimab (EUDRACT) - Jul 15, 2024
P2, N=35, Not yet recruiting, Sponsor: Beijing Chest Hospital, Capital Medical University; Beijing Chest Hospital, Capital Medical University
- | New P2 trial: Low-dose radiotherapy combined with neoadjuvant chemotherapy and cardonilizumab for locally advanced head and neck squamous cell carcinoma: a single-arm, prospective phase II clinical study (EUDRACT) - Jul 15, 2024
P2, N=25, Recruiting, Sponsor: Dongguan People's Hospital; Dongguan People's Hospital
- | New P2 trial: A prospective, single arm phase II clinical study on the induction of cardunizumab and TP regimen combined with chemotherapy and radiotherapy in the treatment of late cervical cancer with fused lymph node outcomes (EUDRACT) - Jul 15, 2024
P2, N=45, Recruiting, Sponsor: Cancer Hospital Affiliated to Guangzhou Medical University; Cancer Hospital Affiliated to Guangzhou Medical University
- | Aqupla (nedaplatin) / Simcere, adebrelimab (SHR-1316) / Jiangsu Hengrui Pharma
New P2 trial: Adebrelimab combined with nab-paclitaxel and nedaplatin in the neoadjuvant treatment of locally advanced resectable esophageal squamous cell carcinoma: a single-arm, exploratory clinical study (EUDRACT) - Jul 15, 2024
P2, N=65, Recruiting, Sponsor: Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital
- | adebrelimab (SHR-1316) / Jiangsu Hengrui Pharma
New P2 trial: Neoadjuvant Adebrelimab plus SOX and Nab-paclitaxel in Resectable Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: A Multicentre, Single-arm, Prospective Phase II Trial (EUDRACT) - Jul 15, 2024
P2, N=36, Recruiting, Sponsor: The First Affiliated Hospital of Dalian Medical Uniersity; The First Affiliated Hospital of Dalian Medical Uniersity
- | Hansizhuang (serplulimab) / Fosun Pharma
New P2 trial: Low-dose radiotherapy combined with serplulimab and albumin paclitaxel plus cisplatin neoadjuvant therapy for locally advanced esophageal cancer: a single-arm, prospective phase II clinical study (EUDRACT) - Jul 15, 2024
P2, N=24, Recruiting, Sponsor: Dongguan People's Hospital; Dongguan People's Hospital
- | Focus V (anlotinib) / Advenchen, Sino Biopharm, TQB2868 / Sino Biopharm
New P2 trial, Metastases: A single-arm, open-label, phase ? clinical trial of TQB2868 injection combined with anlotinib capsule and chemotherapy as first-line treatment for metastatic pancreatic cancer (EUDRACT) - Jul 15, 2024
P2, N=40, Not yet recruiting, Sponsor: Fudan University Shanghai Cancer Center; Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co. LTD
- | Sulanda (surufatinib) / Hutchmed
New P2 trial: Surufatinib combined with gemcitabine plus nab-paclitaxel in patients with locally advanced pancreatic cancer (EUDRACT) - Jul 15, 2024
P2, N=40, Not yet recruiting, Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of
- | AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma
New P2 trial, Combination therapy: Comparing efficacy and safety of dalpiciclib in combination with neoadjuvant endocrine therapy versus neoadjuvant chemotherapy in HR-strong-positive and HER2-negative breast cancer patients: a multicenter, open, prospective Phase II study (EUDRACT) - Jul 15, 2024
P2, N=112, Recruiting, Sponsor: Sun Yat-Sen University Cancer Center; Sun Yat-Sen University Cancer Center
- | Tyvyt (sintilimab) / Eli Lilly, Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
New P2 trial, Metastases: A phase II study on the efficacy and safety of Sintilimab combined with nab-paclitaxel and tegio (aTS) as first-line treatment of unresectable locally advanced, recurrent or metastatic adenocarcinoma of the stomach and gastroesophageal junction (CZTU-1) (EUDRACT) - Jul 15, 2024
P2, N=30, Not yet recruiting, Sponsor: Changzhou Tumor Hospital; Changzhou Tumor Hospital
- | Tevimbra (tislelizumab-jsgr) / BeiGene
New P2 trial: A single-arm, phase II trial evaluating the efficiency and safety of neoadjuvant immunochemotherapy and radical surgery with reduced surgical margin in treating patients with locally advanced (T3-4a) tougue squamous cell carcinoma (EUDRACT) - Jul 15, 2024
P2, N=30, Recruiting, Sponsor: Sun Yat-Sen University Cancer Center; Sun Yat-Sen University Cancer Center
- | New P1 trial: Effect of foot compression therapy on peripheral neuropathy induced by albumin-binding paclitaxel chemotherapy in patients with breast cancer (EUDRACT) - Jul 15, 2024
P1, N=84, Completed, Sponsor: Affiliated Hospital of North Sichuan Medical College; Affiliated Hospital of North Sichuan Medical College
- | Hansizhuang (serplulimab) / Fosun Pharma
Enrollment open: Serplulimab combined with gemcitabine, nab-paclitaxel and stereotactic body radiotherapy as the first-line treatment for patients with metastatic pancreatic adenocarcinoma in China: a multicenter, single-arm, phase II trial (ICSBR) (EUDRACT) - Jul 15, 2024
P2, N=43, Recruiting, Sponsor: West China Hospital, Sichuan University; West China Hospital, Sichuan University
QOL data complement the efficacy/safety of T-DXd after ?1 ET in patients with hormone receptor Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group, AiRuiKa (camrelizumab) / HLB Bio Group
Enrollment open: Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial (clinicaltrials.gov) - Jul 15, 2024
P3, N=164, Recruiting, Sponsor: XIANG YANQUN
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | adebrelimab (SHR-1316) / Jiangsu Hengrui Pharma
New P2 trial: Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC (clinicaltrials.gov) - Jul 15, 2024
P2, N=48, Not yet recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
- || oxaliplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
P1/2 data, Journal, Metastases: Multicenter phase I/II trial of gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer. (Pubmed Central) - Jul 13, 2024
P1/2
Future studies will clarify the benefit of chemotherapy combinations in different settings. This trial is registered with ClinicalTrials.gov, NCT03943043.
- | Tyvyt (sintilimab) / Eli Lilly
Biomarker, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Efficacy and biomarker analysis of second-line nab-paclitaxel plus sintilimab in patients with advanced biliary tract cancer. (Pubmed Central) - Jul 12, 2024
Nab-paclitaxel plus sintilimab is a potentially effective and tolerable second-line regimen for advanced BTC that deserves to be studied in large-scale trials. PD-L1 status and CD8+ T cell infiltration might be promising biomarkers for efficacy prediction.
- ||||| RenovoGem (gemcitabine with RenovoCath) / RenovoRx
Enrollment change, Trial completion date, Trial primary completion date, Metastases: TIGeR-PaC: Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC (clinicaltrials.gov) - Jul 12, 2024
P3, N=190, Recruiting, Sponsor: RenovoRx
PD-L1 status and CD8+ T cell infiltration might be promising biomarkers for efficacy prediction. N=320 --> 190 | Trial completion date: Sep 2023 --> Sep 2026 | Trial primary completion date: Sep 2022 --> Jun 2026
- || Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
P2 data, Journal, Metastases: Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicenter, randomized, phase II study. (Pubmed Central) - Jul 11, 2024
P2
The first-line AS regimen significantly extended both PFS and OS of Chinese patients with advanced PC when compared with the AG regimen, with a comparable safety profile. (ClinicalTrials.gov Identifier: NCT03636308).
- | albumin-bound paclitaxel / Generic mfg.
New trial, Metastases: A Clinical Study of Albumin-bound Paclitaxel/Granulocyte-based Therapy for Recurrent/Metastatic Breast Cancer (clinicaltrials.gov) - Jul 11, 2024
P=N/A, N=1, Recruiting, Sponsor: JIANG LONGWEI
- | Tybost (cobicistat) / Gilead
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: IntenSify: A Trial of Cobicistat and Gemcitabine and Nab-Paclitaxel in Patients With Advanced Stage or Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov) - Jul 10, 2024
P1, N=6, Terminated, Sponsor: German Cancer Research Center
(ClinicalTrials.gov Identifier: NCT03636308). N=18 --> 6 | Trial completion date: Feb 2025 --> Mar 2024 | Recruiting --> Terminated | Trial primary completion date: Aug 2024 --> Mar 2024; lack of efficacy paired with high toxicity
- | Tyvyt (sintilimab) / Eli Lilly
Retrospective data, Journal, Combination therapy, Real-world evidence, Real-world: Efficacy and safety of sintilimab in combination with chemotherapy for recurrent extensive-stage small cell lung cancer: a real-world retrospective study. (Pubmed Central) - Jul 10, 2024
Sintilimab in combination with chemotherapy is superior to single-agent chemotherapeutic treatment as second-line or later therapy in ES-SCLC patients who have not received prior immunotherapy. These results need to be confirmed in future clinical trials.
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New trial, Metastases: NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus AG Combined With PD-1 Sequential Radiotherapy as First-line Treatment of Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Jul 9, 2024
P=N/A, N=40, Recruiting, Sponsor: Du Juan